Drug Discovery & Molecular Design - software & AI news

Daily news on software, AI, and companies shaping drug discovery & molecular design.

Showing 375 results
Press release cover image

Sep 22, 2026

Tsingke Enables High-Throughput Validation of AI-Designed Proteins and Antibodies

BEIJING, Sept. 22, 2026 /PRNewswire/ -- Tsingke today announced an integrated high-throughput validation workflow designed to help researchers experimentally evaluate large libraries of AI-designed proteins and antibodies. Combining gene synthesis, parallel expression, high-throughput screening, scale-up production, purification and quantitative binding analysis, the workflow enables researchers to move large numbers of computationally designed candidates into experimental testing and advance pr
Press release cover image

Sep 22, 2026

Lunai Bioworks (NASDAQ: LNAI) Expands Parkinson's Platform Through Exclusive Tanaist Agreement

Exclusive worldwide agreement adds human cellular validation to Lunai's AI-driven Parkinson's workflow, connecting patient-derived subtypes with disease mechanisms, biomarkers and therapeutic targetsSACRAMENTO, Calif., Sept. 22, 2026 /PRNewswire/ -- Lunai Bioworks, Inc. (Nasdaq: LNAI), a biology-first AI drug discovery company, today announced an exclusive worldwide license and collaboration agreement with Tanaist, Inc. that adds human cellular phenotyping to Lunai's growing Parkinson's disease
Minimalist illustration of a molecular structure

Sep 22, 2026

Apheris Announced the Results of their Federated Learning Co-Folding Initiative—Now Four Big Pharma Are Betting Bigger

Four major pharmaceutical companies—AbbVie, AstraZeneca, Bristol Myers Squibb, and Johnson & Johnson—are collaborating on a new initiative to enhance drug discovery through AI-driven predictions of molecular interactions. This project, named AISB Bind, is a significant step in leveraging federated learning to optimize drug development processes.The AISB Bind initiative, announced by the AI Structural Biology (AISB) Network and supported by Apheris and the AlQuraishi Lab at Columbia University, a
Press release cover image

Sep 22, 2026

Envisagenics and Boehringer Ingelheim Enter Multi-Target Collaboration to Develop First-in-Class Precision Therapies Based on RNA Splicing-Derived Targets for Hard-to-Treat Cancers

Envisagenics’ AI-powered SpliceCore® platform opens up alternative RNA splicing – one of the last largely untapped sources of tumor-specific targets – for precision oncologyBoehringer Ingelheim may apply selected targets across multiple modalities, including antibody-drug conjugates, T-cell engagers and multispecific antibodiesEnvisagenics is eligible to receive more than US$1 billion in potential payments, including an upfront payment, research funding, option fees and development, regulatory a
A minimalist representation of a small-molecule drug structure in flat design.

Sep 22, 2026

Iambic files IPO after signing up AbbVie as new partner

Iambic Therapeutics has recently filed for an IPO on Nasdaq, following a significant partnership with AbbVie, which enhances its capabilities in AI-driven drug discovery.The San Diego-based company aims to secure funding to propel its lead drug candidate, IAM1363, an oral HER2 inhibitor currently in phase 1 trials for HER2-positive breast cancer and non-small cell lung cancer. Iambic's AI platform employs a closed-loop system that integrates AI with automated lab processes, allowing for the deve
E. coli and protein silhouette

Sep 22, 2026

AI drug race moves from finding candidates to proving they work

The landscape of AI in drug development is evolving, shifting focus from merely identifying potential candidates to rigorously validating their effectiveness in the lab.Recent advancements in AI technology are enabling researchers to not only screen vast libraries of compounds but also to form strategic partnerships with pharmaceutical companies. For instance, Novorex is actively testing AI-selected drug candidates, utilizing organisms like E. coli to evaluate whether these compounds effectively
Press release cover image

Sep 21, 2026

AbbVie and Iambic Announce Collaboration to Accelerate AI-driven Drug Discovery

Multi-year partnership applies Iambic's AI platform to speed up small molecule drug discovery in immunology, neuroscience and oncology Companies to pursue programs with both first-in-class and best-in-class potential, combining Iambic's molecular superintelligence platform with AbbVie's therapeutic area expertiseNORTH CHICAGO, Ill. and SAN DIEGO, Sept. 21, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Iambic, a clinical-stage life sciences and technology company developing novel medicines through
A minimalist representation of a molecule symbolizing AI agents in drug discovery.

Sep 18, 2026

Virtual Biotech Company Puts 37,000 AI Agents to Work on Drug Discovery

Stanford researchers have developed a groundbreaking virtual biotech company leveraging 37,000 AI agents to enhance drug discovery, significantly improving the chances of clinical trial success.The pharmaceutical industry faces immense challenges, with around 90% of drugs failing to reach the market due to various factors, including poor translation of lab results to patient outcomes and unforeseen side effects. To address these issues, a team at Stanford has created a virtual biotech framework
Minimalist illustration of a pill representing drug development

Sep 18, 2026

London-based Big Picture Bio emerges from stealth with €2.55 million to develop AI-designed cancer drug combinations

Big Picture Bio, a London-based biotech startup, has officially launched with €2.55 million in funding to develop AI-driven cancer therapies.The funding consists of a €1.75 million pre-Seed round led by Kadmos Capital and Exceptional Ventures, complemented by €815k in non-dilutive support from Innovate UK. Founders Dr. Kerstin Papenfuss and Dr. Mark Hammond, both with extensive backgrounds in therapeutics and technology, aim to revolutionize drug development by using AI to predict the effectiven
Press release cover image

Sep 17, 2026

Alloy Therapeutics Selected to Join the World Economic Forum’s Unicorns Community

Alloy will contribute its perspective on building collaborative, AI-powered biotechnology infrastructure to accelerate the discovery and development of better medicinesBOSTON--(BUSINESS WIRE)--Alloy Therapeutics, a Product Development Organization (PDO), today announced that it has been selected to join the World Economic Forum’s Unicorns Community, an invitation-only group of high-growth private companies valued at more than $1 billion and recognized for their potential to shape industries and
A flat illustration of a drug molecule silhouette on a solid background.

Sep 17, 2026

Novo taps Anthropic's Claude AI for drug discovery

Novo has integrated Anthropic's Claude AI into its drug discovery efforts, aiming to enhance research and development processes.Following the launch of Anthropic's AI workbench, Novo, formerly known as Novo Nordisk, has formed a partnership to leverage Claude and Claude Science for improved scientific reasoning. This collaboration will focus on addressing specific drug discovery challenges identified by Novo's scientists and computational teams, facilitating the development of tailored solutions
Press release cover image

Sep 17, 2026

Ginkgo Datapoints Announces Partnership with TuneLab to Close the Gap between AI Models and Lab Data

Integration puts Ginkgo’s biological data generation services at the heart of the industry’s most prominent AI-driven drug discovery networkBOSTON--(BUSINESS WIRE)--Ginkgo Bioworks (NYSE: DNA) today announced that its Ginkgo Datapoints offering has entered into a new agreement with Lilly TuneLab, a collaborative AI/ML drug discovery platform created by Eli Lilly and Company (Lilly). TuneLab supports biotech innovation by enabling participating companies to access AI/ML drug discovery models trai